CimetrAT Patent Approved by European IP Office

RNS Number : 8719I

MGC Pharmaceuticals Limited

21 April 2022

 

MGC Pharmaceuticals Ltd.

MGC Pharma Patent Application for CimetrA™ Approved by European IP Office

21 April 2022

ASX, LSE: MXC

Key Highlights :

· Patent granted for MGC Pharma's proprietary Investigational Medical Product, CimetrA ™ , by the Slovenian Intellectual Property Office.    

· CimetrA ™ is designed for multiple therapeutic applications including the treatment acute and chronic inflammation associated with variants of influenza,   viral diseases including COVID-19, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infections.

· CimetrA™utilises Graft Polymer's proprietary GraftBio™ SNEDDS technology (Self-Nano Emulsifying Drug Delivery System) ,  a unique platform designed to deliver active ingredients more effectively and in higher concentrations to cells, improving the bioavailability and synergy of natural active ingredients.

· MGC Pharma continues to progress CimetrA ™ through the clinical trial process to demonstrate the efficacy and pharmacokinetic profile of the treatment.

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the grant of a Patent for the Company's Investigational Medical Product, CimetrA^TM , from the Slovenian Intellectual Property Office ( SIPO ).

The Patent

The grant of the Patent provides MGC Pharma commercial protection over the intellectual property associated with CimetrA^TM 's unique formation and manufacturing process for a period of 20 years.

CimetrA^TM is a nano-micellular pharmaceutical synergetic composition consisting of Curcumin, Boswellia  and optionally, Artemisinin, Cannabinoids and/or Nitroxides. The composition can be manufactured in liquid or solid pharmaceutically acceptable carriers, and has antioxidant, anti-inflammatory and immuno-modulating properties, and is designed for multiple therapeutic applications utilising Graft Polymer's GraftBio^TM self-nanoemulsifying drug delivery system (SNEDDS).

The Patent sets out the specific antioxidant, anti-inflammatory, and immune-modulating properties of CimetrA™ , which is designed for multiple therapeutic applications including the prevention of systemic chronic inflammation, including the treatment and alleviation of the Cytokine Storm, a symptom of an infection of severe acute respiratory syndrome coronavirus 2 (the cause of COVID-19) and heavy variants of influenza, as well as various types of cancer.[1] This is in addition to its potential efficacy in relation to the regulation of the human body's circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal, and parasitic infections. It's wide range of uses as a treatment highlights its versatility as an IMP.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "The grant of the Patent by the Slovenian Intellectual Property Office is a key milestone for MGC Pharma, with the Patent acknowledging the uniqueness of CimetrA's formulation, as well as providing commercial protection of the Intellectual Property used to manufacture the product.

The grant of the Patent is a further step forward for MGC Pharma in its strategy to development of a range of proprietary products, and becoming a wholly bio-pharma company with the ability to produce high-grade pharmaceutical products to treat the symptoms of some of the most debilitating conditions. "

--Ends--

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - Epilepsy and Dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

---

1.  Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531591/#:~:text=%E2%80%9CCytokine%20storm%E2%80%9D%20or%20%E2%80%9Ccytokine,in%20graft%20versus%20host%20disease;

https://blog.dana-farber.org/insight/2021/07/what-is-a-cytokine-storm/

 

END

 

 

REAKZGZDKMZGZZG